A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat

PHASE2CompletedINTERVENTIONAL

Enrollment

107

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

May 20, 2024

Study Completion Date

May 20, 2024

Conditions

Subcutaneous Fat

Interventions

DRUG

CBL-514 Injection

Formulated as an injectable CBL-514 solution at a concentration of 5 mg/mL.

OTHER

0.9% Sodium Chloride

Sodium Chloride (0.9% NaCl) placebo for injection

Trial Locations (1)

Investigational site 1, Pflugerville